[ XXXX : considerations on the frequency and mid-term course of its juvenile form].

@entity1 @entity6369 @entity625 @entity1530 @entity9066 @entity6104 @entity1691 @entity158 @entity2720 @entity1681
@entity6104 ( @entity6104 ) is not common in @entity1 and adolescents. From 1982 to 1987 we have seen 13 pediatric @entity1 (8 male and 5 female) with clinical manifestations that characterized @entity6104 . Age of onset was 13 years. Clinical findings have been @entity625 (100%) involving the knee and @entity158 (84%), @entity158 (38%). One to three weeks before joint involvement, six @entity1 (46%) complained of @entity6369 , 5 (38%) had @entity1681 and two @entity1 had both. 46% of the @entity1 had @entity1530 antigen. Radiologic findings were sacroileitis in five @entity1 and @entity9066 . All @entity1 were treated with non-steroidal antiinflammatory therapy and, in general, there was a clinical remission in 1-3 months. Nevertheless, after 4 years of follow up, 2 @entity1 had acute relapsing @entity625 and 4 had chronic @entity2720 . Three @entity1 have developed secondary @entity1691 . @entity6104 is not all that infrequent in pediatric @entity1 with joint involvements if one looks for @entity6369 , @entity1681 , eye involvement and cutaneous manifestations. The clinical course is favorable, but there might be some chronic or relapsing cases. Some @entity1 can developed secondary @entity1691 . For that reason a prolonged follow up of these @entity1 is necessary.
